Percutaneous coronary intervention with implantation of a sirolimus-eluting stent with abluminal coating: First cases in Cuba
Abstract
Introduction: Cardiovascular diseases represent the leading causes of death in the world and in Cuba. Percutaneous coronary intervention with drug-eluting stents has improved the treatment and evolution of these patients.
Objective: To describe the clinical and angiographic characteristics of patients treated with ihtDEStiny stents and to identify major cardiac adverse events during clinical follow-up.
Method: An observational, analytical and prospective study was carried out at the Instituto de Cardiología y Cirugía Cardiovascular of Havana, from June 2019 to December 2020, including the first 50 consecutive patients treated in Cuba with abluminal-coated sirolimus-eluting stent.
Results: The mean age was 61.5 years old, with a predominance of males (88%). The predominant cardiovascular risk factor was high blood pressure (37 patients [74%]), followed by diabetes mellitus (13 [26%]). Seventy-nine stenoses were treated with a predominance of type B2 (48.1%) and an average of 1.58 stents per patient were implanted, in 60% of cases directly. The left anterior descending was the most affected coronary artery, the immediate success of the procedure was 98.7% and few major cardiac adverse events were detected after a clinical follow-up at 6 and 12 months.
Conclusions: The treated patients show profiles of age, gender and risk factors similar to those of the rest of patients with coronary artery disease. The sirolimus drug-eluting stents used in this study are safe and guarantee a period free from major cardiac adverse events.
Downloads
References
1. Ministerio de Salud Pública. Anuario Estadístico de Salud 2015. La Habana: Dirección de Registros Médicos y Estadísticas de Salud; 2016.
2. Pipkin M, Ochoa JP, Andrés SM, Verón FL, Stampone G, Blanco G, et al. Cirugía de reemplazo valvular aórtico en pacientes octogenarios: resultados perioperatorios y seguimiento a mediano plazo. Rev Arg Cardiol. 2014;82(1):13-20.
3. Cosselman KE, Navas-Acien A, Kaufman JD. Environmental factors in cardiovascular disease. Nat Rev Cardiol. 2015;12(11):627-42. DOI: https://doi.org/10.1038/nrcardio.2015.152
4. Ministerio de Salud Pública. Anuario Estadístico de Salud 2019. La Habana: Dirección de Registros Médicos y Estadísticas de Salud; 2020.
5. González Veliz A, López Ferrero LH, Rodríguez Nande LM, Llerena Rojas LD, Alfonso Rodríguez E, Martínez Benítez P. Intervencionismo coronario percutáneo en oclusiones totales crónicas. Rev Cuban Cardiol [Internet]. 2019 [citado 28 Feb 2021];25(2). Disponible en: http://www.revcardiologia.sld.cu/index.php/revcardiologia/article/view/815/pdf
6. Grüntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet. 1978;311(8058):263. DOI: https://doi.org/10.1016/s0140-6736(78)90500-7
7. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 1987;316(12):701-6. DOI: https://doi.org/10.1056/nejm198703193161201
8. Torrado J, Buckley L, Durán A, Trujillo P, Toldo S, Valle Raleigh J, Abbate A, Biondi-Zoccai G, Guzmán LA. Restenosis, Stent Thrombosis, and Bleeding Complications: Navigating Between Scylla and Charybdis. J Am Coll Cardiol. 2018 Apr 17;71(15):1676-95. DOI: https://doi.org/10.1016/j.jacc.2018.02.023
9. Thipparaboina R, Khan W, Domb AJ. Eluting combination drugs from stents. Int J Pharm. 2013;454(1):4-10. DOI: https://doi.org/10.1016/j.ijpharm.2013.07.005
10. Foerst J, Vorpahl M, Engelhardt M, Koehler T, Tiroch K, Wessely R. Evolution of coronary stents: From bare-metal stents to fully biodegradable, drug-eluting stents. Comb Prod Ther. 2013;3:9-24. DOI: https://doi.org/10.1007/s13556-013-0005-7
11. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213-60. DOI: https://doi.org/10.1093/eurheartj/ehx419
12. Iqbal J, Gunn J, Serruys PW. Coronary stents: historical development, current status and future directions. Br Med Bull. 2013;106:193-211. DOI: https://doi.org/10.1093/bmb/ldt009
13. Kang SH, Chae IH, Park JJ, Lee HS, Kang DY, Hwang SS, et al. Stent thrombosis with drug-eluting stents and bioresorbable scaffolds: Evidence from a network meta-analysis of 147 trials. JACC Cardiovasc Interv. 2016;9(12):1203-12. DOI: https://doi.org/10.1016/j.jcin.2016.03.038
14. Ali ZA, Gao R, Kimura T, Onuma Y, Kereiakes DJ, Ellis SG, et al. Three-Year Outcomes With the Absorb Bioresorbable Scaffold: Individual-Patient-Data Meta-Analysis From the ABSORB Randomized Trials. Circulation. 2018;137(5):464-79. DOI: https://doi.org/10.1161/circulationaha.117.031843
15. Hu T, Yang J, Cui K, Rao Q, Yin T, Tan L, et al. Controlled slow-release drug-eluting stents for the prevention of coronary restenosis: Recent progress and future prospects. ACS Appl Mater Interfaces. 2015;7(22):11695-712. DOI: https://doi.org/10.1021/acsami.5b01993
16. Chen W, Habraken TC, Hennink WE, Kok RJ. Polymer-Free Drug-Eluting Stents: An Overview of Coating Strategies and Comparison with Polymer-Coated Drug-Eluting Stents. Bioconjug Chem. 2015;26(7):1277-88. DOI: https://doi.org/10.1021/acs.bioconjchem.5b00192
17. Muramatsu T, Onuma Y, Zhang YJ, Bourantas CV, Kharlamov A, Diletti R, et al. Avances en el tratamiento mediante intervención coronaria percutánea: El stent del futuro. Rev Esp Cardiol. 2013;66(6):483-96. DOI: https://doi.org/10.1016/j.rec.2012.12.009
18. Pilgrim T, Piccolo R, Heg D, Roffi M, Tüller D, Muller O, et al. Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial. Lancet. 2018;392(10149):737-46. DOI: https://doi.org/10.1016/s0140-6736(18)31715-x
19. Iglesias JF, Muller O, Heg D, Roffi M, Kurz DJ, Moarof I, et al. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. Lancet. 2019;394(10205):1243-53. DOI: https://doi.org/10.1016/s0140-6736(19)31877-x
20. López Pérez JE, Filgueiras Frías E, Aroche Aportela R, Llerena Rojas L, López Ferrero L, Obregón Santos AG, et al. Seguimiento a cuatro años de pacientes con stent Firebird liberador de sirolimus en Cuba. Rev Fed Arg Cardiol 2010;39(2):105-9.
21. Park KW, Rhee TM, Kang HJ, Koo BK, Gwon HC, Yoon JH, et al. Randomized prospective comparison of everolimus-eluting vs. sirolimus-eluting stents in patients undergoing percutaneous coronary intervention —3-year clinical outcomes of the EXCELLENT randomized trial—. Circ J. 2018;82(6):1566-74. DOI: https://doi.org/10.1253/circj.cj-17-0677
22. McSweeney JC, Rosenfeld AG, Abel WM, Braun LT, Burke LE, Daugherty SL, et al. Preventing and Experiencing Ischemic Heart Disease as a Woman: State of the Science: A Scientific Statement From the American Heart Association. Circulation. 2016;133(13):1302-31. DOI: https://doi.org/10.1161/cir.0000000000000381
23. Kakizaki R, Minami Y, Katamine M, Katsura A, Muramatsu Y, Hashimoto T, Meguro K, Shimohama T, Ako J. Clinical outcome of biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with diabetes. Cardiovasc Diabetol [Internet]. 2020 [citado 7 Mar 2021];19(1):162. Disponible en: https://doi.org/10.1186/s12933-020-01145-x
24. Gasior P, Gierlotka M, Szczurek-Katanski K, Osuch M, Roleder M, Hawranek M, et al. Biodegradable polymer-coated thin strut sirolimus-eluting stent versus durable polymer-coated everolimus-eluting stent in the diabetic population. Cardiol J. 2021;28(2):235-243. DOI: https://doi.org/10.5603/cj.a2019.0111
25. Abhyankar A, Abizaid A, Chamié D, Rathod M. Comparison of neointimal coverage between ultrathin biodegradable polymer-coated sirolimus-eluting stents and durable polymer-coated everolimus-eluting stents: 6 months optical coherence tomography follow-up from the TAXCO study. Catheter Cardiovasc Interv. 2021;97(3):423-30. DOI: https://doi.org/10.1002/ccd.28833
26. Iñiguez A, Chevalier B, Richardt G, Neylon A, Jiménez VA, Kornowski R, et al. Comparison of long-term clinical outcomes in multivessel coronary artery disease patients treated either with bioresoarbable polymer sirolimus-eluting stent or permanent polymer everolimus-eluting stent: 5-year results of the CENTURY II randomized clinical trial. Catheter Cardiovasc Interv. 2020;95(2):175-84. DOI: https://doi.org/10.1002/ccd.28224
27. Fortich F, Uribe CE, Tenorio CA, Eusse CA, Ortiz JC. Arteria coronaria descendente anterior doble: reporte de un caso y revisión de la literatura. Rev Colomb Cardiol. 2012;19(2):96-9.
28. Saito S, Valdes-Chavarri M, Richardt G, Moreno R, Iniguez Romo A, Barbato E, et al. A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease) trial. Eur Heart J. 2014;35(30):2021-31. DOI: https://doi.org/10.1093/eurheartj/ehu210
29. King SB, Smith SC, Hirshfeld JW, Jacobs AK, Morrison DA, Williams DO, et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation. 2008;117(2):261-95. DOI: https://doi.org/10.1161/circulationaha.107.188208
30. Shen L, Yang W, Yin JS, Liu XB, Wu YZ, Sun AJ, et al. Nine-month angiographic and two-year clinical follow-up of novel biodegradable-polymer arsenic trioxide-eluting stent versus durable-polymer sirolimus-eluting stent for coronary artery disease. Chin Med J (Engl). 2015;128(6):768-73. DOI: https://doi.org/10.4103/0366-6999.152490
31. Kuramitsu S, Kazuno Y, Sonoda S, Domei T, Jinnouchi H, Yamaji K, et al. Vascular response to bioresorbable polymer sirolimus-eluting stent vs. permanent polymer everolimus-eluting stent at 9-month follow-up: An optical coherence tomography sub-study from the CENTURY II trial. Eur Heart J Cardiovasc Imaging. 2016;17(1):34-40. DOI: https://doi.org/10.1093/ehjci/jev203
32. Kandzari DE, Mauri L, Koolen JJ, Massaro JM, Doros G, Garcia-Garcia HM, et al. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. Lancet. 2017;390(10105):1843-52. DOI: https://doi.org/10.1016/s0140-6736(17)32249-3
33. Obregón Oblitas J, Ribamar Costa J, Siqueira DA, Maldonado A, Barreira G, Slhessarenko J, et al. Implante de stents con o sin predilatación en pacientes con síndrome coronaria aguda sin supradesnivel del segmento ST. Rev Bras Cardiol Invasiva. 2013;21(4):338-43.
34. Barbosa MH, Moreira TM, Tavares JL, Andrade EV, Bitencourt MN, Bitencourt KB, et al. Complicaciones en pacientes sometidos a angioplastia coronaria transluminal percutánea. Enferm Glob. 2013;12(31):14-23.
35. Zbinden R, Piccolo R, Heg D, Roffi M, Kurz DJ, Muller O, et al. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable-polymer everolimus-eluting stent for percutaneous coronary revascularization: 2-year results of the BIOSCIENCE trial. J Am Heart Assoc [Internet]. 2016 [citado 7 Mar 2021];5(3):e003255. Disponible en: https://doi.org/10.1161/jaha.116.003255
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
